Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

APGE

Phase 1

APG333

Asthma, COPD and broader inflammatory and immunology conditions

H2 2025

12/10/24- Dosed first patient. Interim safety and pharmacokinetic data in H2 2025

Data readout

INAB

Phase 2

INB-400

Glioblastoma (GBM)

2025

10/12/23- Initiates patient enrollment. 4/30/24- Dosed first patient in Ph2. 3/13/25- Pause further enrollment & explore partnership opportunities. Report additional findings at upcoming medical meetings in 2025.

Data readout

RPTX

Phase 1

RP-1664

Solid tumors (TRIM37 )

Q4 2025

LIONS trial. 2/15/24- Dosed first patient. 3/3/25- Initial topline data in Q4 2025 and trial completion w/ final data readout of PoC in Mid-2026.

Data readout

ITOS

Phase 1

EOS-984

Solid tumors

2025

APT-008 trial. 8/8/23- Initiated enrollment. 11/12/24- Topline data in 2025.

Data readout

SCYX

Phase 3

SCY-078

Invasive candidiasis

2025

MARIO study. 3/12/25- To restart trial in 2025, pending FDA's lifting of clinical hold.

Initiation

NCNA

Phase 1/2

NUC-7738 (ProTide) +/- pembrolizumab

Solid Tumors, melanoma

2025

NuTide:701 study. 9/14/24- Presented final data at ESMO '24. 3/20/25- Initiate expansion study, announce data in 2025 and obtain regulatory guidance from FDA for a pivotal study design.

Initiation

ACIU

Phase 1

ACI-15916 (a-syn-PET tracer)

Parkinson's disease

H2 2025

3/13/25- Completed pre-IND study. Data readout (Ph1) in H2 2025.

Data Readout

NUVL

Phase 2

Zidesamtinib (NVL-520)

ROS1-positive NSCLC (Non-small cell lung cancer)

2025

ARROS-1 Trial. 8/9/24- Ph2 enrollment ongoing. 9/14/24- Presented trial update at ESMO '24. Report pivotal trial data in 2025.

Data Readout

VYNE

Phase 1b

VYN202

Moderate-to-severe plaque psoriasis and moderate-to-severe adult-onset rheumatoid arthritis

YE 2025

5/6/24- IND cleared. 9/12/24- Reported Ph1a SAD data. 2/19/25- Initiated trial. 3/6/25- Trial results by year-end 2025.

Data readout

ALNY

Phase 2

Zilebesiran (ALN-AGT)

Hypertension

H2 2025

w/ Roche KARDIA-1, 2 & 3 trials. 3/5/24 Reports positive KARDIA-2 topline results. 5/9/24 Initiated KARDIA-3 study in early 2024 w/ FPI in April 2024. 2/13/25- KARDIA-3 completed enrollment. 2/25/25- KARDIA-3 results in H2 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20